Cargando…
In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease
BACKGROUND: Liver disease (LD) prolongs mirtazapine half‐life in humans, but it is unknown if this occurs in cats with LD and healthy cats. HYPOTHESIS/OBJECTIVES: To determine pharmacokinetics of administered orally mirtazapine in vivo and in vitro (liver microsomes) in cats with LD and healthy cats...
Autores principales: | Fitzpatrick, Rikki L., Quimby, Jessica M., Benson, Kellyi K., Ramirez, Dominique, Sieberg, Liberty G., Wittenburg, Luke A., Gustafson, Daniel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272035/ https://www.ncbi.nlm.nih.gov/pubmed/30307637 http://dx.doi.org/10.1111/jvim.15237 |
Ejemplares similares
-
Pharmacokinetics of isavuconazole in healthy cats after oral and intravenous administration
por: Woerde, Dennis J., et al.
Publicado: (2022) -
Assessment of compounded transdermal mirtazapine as an appetite
stimulant in cats with chronic kidney disease
por: Quimby, Jessica M, et al.
Publicado: (2019) -
The fecal microbiome and serum concentrations of indoxyl sulfate and p‐cresol sulfate in cats with chronic kidney disease
por: Summers, Stacie C., et al.
Publicado: (2018) -
The pharmacokinetics of gabapentin in cats
por: Adrian, Derek, et al.
Publicado: (2018) -
Biological variation of major gut‐derived uremic toxins in the serum of healthy adult cats
por: Summers, Stacie, et al.
Publicado: (2021)